Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TITAN: GB001 in Chronic Rhinosinusitis
NCT03956862Phase 2Completed
- Sponsor
- Gossamer Bio
- Start
- May 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in chronic rhinosinusitis (CRS) comparing GB001 Arm with Placebo Arm (2 arms). Primary endpoint: Sino-Nasal Outcome Test-22 Total Score at 16 weeks. Started May 2019; status: completed.
02
Drugs
GB001
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on NCT03956862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03956862.